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Results. Median age of all patients was 70 years (range 56–78). Morbidities affecting refractory bleeding included smoking (10), dia-
betes (22), cardiovascular disease (15), anticoagulant therapy (9) and gastrointestinal disease (11). Themedian lowest haemoglobin
level was 9.6 gr/dl. Median time between completion of radiotherapy and ﬁrst session of APC was 13 months (range 4–41). Ninety-
four therapeutic sessions were performed (median 3 sessions). Median time follow-up was 14.5 months (range 2–61). Complete
response with resolved rectal bleeding was achieved in 23 patients (77%), partial response in 5 (16%) and no control in 2 (6%). None
of 30 patients required transfusion following therapy. APC was well tolerated excluding 1 case that developed a rectal ulceration.
Conclusions. APC is a safe and effective alternative in the management of persistent rectal bleeding radiation-induced proctitis.
http://dx.doi.org/10.1016/j.rpor.2013.03.494
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Introduction. Late rectal toxicity in patients treated of prostate cancer with three-dimensional conformal radiotherapy (3D-CRT)
is related to the volume of rectum irradiated. The recommendations of the international consensus (QUANTEC) to limit rectal
toxicity to V50<50% and V70<20%. The values may vary according to calculation algorithm. Algorithm used in our center is the
Pencil-Beam Convolution (PBC), while the algorithm Acuros (AC) has been recently implemented.
Objective. To compare the dosimetric parameters with the PBC and AC algorithms for patients with rectal toxicity grade 2/3 as
measured according to the CTCv3 criteria in prostate cancer patients treated by 3D-CRT to determine the impact of the algorithm
in toxicity.
Method. Between 06/2006 and 06/2008, 257 prostate cancer patients were treated with 3D-CRT. Doses for prostate and seminal
vesicles (PTV1) was 50Gy and 76Gy for prostate (PTV11). Rectal doses were limited to: V50<50% and V70<20%. A total of 12 (4.7%)
patients had rectal toxicity >2 was measured according to CTVv3 requiring hyperbaric oxygen treatment. Dose distributions were
calculated by the PBC and AC algorithm. In order to compare both algorithms, the same planiﬁcation volumes were used. Mean
prostate and rectal dose, V50 and V70 to the rectum and maximum–minimum range PTV95% of the dose were analyzed.
Results. Mean dose for PTV1 plus PTV11 by PBC was 74.58±1.44Gy within 2Gy range, while with AC was 73.58±1.3Gy, range of
4Gy. The 95% isodose 74Gy of PTV1 coincided with both algorithms. The V50 and V70 was 62% and 32% with PBC and 58% and
30% for AC. The statistical comparisons were not signiﬁcant.
Conclusions. PBC and AC algorithms calculate similarly rectal doses of patients treated for prostate cancer with 3D-CRT. We have
not observed any signiﬁcant change in the parameters studied.
http://dx.doi.org/10.1016/j.rpor.2013.03.495
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Introduction. Considering that the a/b ratio for prostate tumors is low, we could yield a clinical beneﬁt by increasing the dose per
fraction, since tumor cells show greater sensitivity to fractionation than adjacent organs at risk.
Purpose. Assessment of long-term tolerance in patients treated with hypofractionated radiotherapy in our Center. Assessment
of PSA levels in the ﬁrst and second years.
Method and material. Between January 2010 and May 2012, 59 men were treated at the Department of Radiation Oncology of the
Hospital Complex of Jaén, with ages comprised between 46 and 77 years old (average 68 years old), KPS 90–100%. They were
diagnosed with prostate Adenocarcinoma. PSA between 4 and 188 (average 14.5ng/ml), Gleason 6 (64%), 7 (22%), 8 (8%), 9 (5%),
clinical stage cT1c (64%), cT2 (17%), cT3 (19%). 76% of concomitant treatments with androgen deprivation.
Results. The administered dosewas from 69.9 to 75.9Gy (average 74.3Gy), in a fractionation of 2.3Gy per day, ﬁve days aweek, with
7 ﬁelds (97%), 3D conformal radiotherapy and 18 MV photons. The tolerance after monitoring for a minimum of 6 months (7–36
months, average 15 months) was excellent, showing gastrointestinal toxicity: G0 in 88%, G1 in 7% and G2 in 5%. In a genitourinary
level it was G0 in 90%, G1 in 10%. PSA was determined one year after completed in 51 patients. 2 patients developed distant
disease. 11 patients without androgen blockade maintained PSA average of 1.31ng/ml. 38 patients with androgen blockade had
PSA average of 0.25ng/ml. PSA was monitored in 9 patients after 2 years. 2 of them without androgen blockade with a PSA average
of 1.17ng/ml. The other 7 with androgen blockade and PSA average of 0.07ng/ml.
Conclusions. The hypofractionated treatment shows an excellent medium-term tolerance. Greater monitoring is needed to deter-
mine the long-term effects and ensure its effectiveness in locoregional control.
http://dx.doi.org/10.1016/j.rpor.2013.03.496
